Information  X 
Enter a valid email address

ReNeuron Group plc (RENE)

  Print      Mail a friend

Monday 18 March, 2019

ReNeuron Group plc

Alliance for Regenerative Medicine presentation

RNS Number : 1790T
ReNeuron Group plc
18 March 2019


18 March 2019



ReNeuron Group plc

("ReNeuron" or the "Company")


ReNeuron to Present at the Alliance for Regenerative Medicine's

Cell & Gene Therapy Investor Day


ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day on Thursday, March 21, 2019 at 9:10 am ET (13:10 pm GMT) at The Metropolitan Club in New York City.

A live and archived webcast of the presentation will be available on the Webcasts & Presentations page of the Company's website at








+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer


+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

Argot Partners

Stephanie Marks, Claudia Styslinger

+ 00 1 212 600 1902

Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

Nplus1 Singer Advisory LLP

+44 (0) 20 7496 3000

Mark Taylor (Joint Broker)



About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t